Cancer and Metastasis Reviews

, Volume 21, Issue 2, pp 147–158 | Cite as

Vitamin D-related Therapies in Prostate Cancer

  • Candace S. Johnson
  • Pamela A. Hershberger
  • Donald L. Trump
Article

Abstract

Calcitriol or 1,25-dihydroxycholecalciferol (vitamin D) is classically known for its effects on bone and mineral metabolism. Epidemiological data suggest that low vitamin D levels increase the risk and mortality from prostate cancer. Calcitriol is also a potent anti-proliferative agent in a wide variety of malignant cell types including prostate cancer cells. In prostate model systems (PC-3, LNCaP, DU145, MLL) calcitriol has significant anti-tumor activity in vitro and in vivo. Calcitriol's effects are associated with an increase in cell cycle arrest, apoptosis, differentiation and in the modulation of growth factor receptors. Calcitriol induces a significant G0/G1 arrest and modulates p21Waf1/Cip1 and p27Kip1, the cyclin dependent kinase inhibitors. Calcitriol induces PARP cleavage, increases the bax/bcl-2 ratio, reduces levels of phosphorylated mitogen-activated protein kinases (P-MAPKs, P-Erk-1/2) and phosphorylated Akt (P-Akt), induces caspase-dependent MEK cleavage and up-regulation of MEKK-1, all potential markers of the apoptotic pathway. Glucocorticoids potentiate the anti-tumor effect of calcitriol and decrease calcitriol-induced hypercalcemia. In combination with calcitriol, dexamethasone results in a significant time- and dose-dependent increase in VDR protein and an enhanced apoptotic response as compared to calcitriol alone. Calcitriol can also significantly increase cytotoxic drug-mediated anti-tumor efficacy. As a result, phase I and II trials of calcitriol either alone or in combination with the carboplatin, paclitaxel, or dexamethasone have been initiated in patients with androgen-dependent and -independent prostate cancer and advanced cancer. Patients were evaluated for toxicity, maximum tolerated dose (MTD), schedule effects, and PSA response. Data from these studies indicate that high-dose calcitriol is feasible on an intermittent schedule, the MTD is still being delineated and dexamethasone or paclitaxel appear to ameliorate toxicity. Studies continue to define the MTD of calcitriol which can be safely administered on this intermittent schedule either alone or with other agents and to evaluate the mechanisms of calcitriol effects in prostate cancer.

calcitriol vitamin D VDR vitamin D analogues preclinical studies animal models 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bikle DD, Pillai S: Vitamin D, calcium, and epidermal differentiation. Endocrine Rev 14: 3–19, 1993 155Google Scholar
  2. 2.
    Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. New Engl J Med 320: 980–991, 1989Google Scholar
  3. 3.
    Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889–895, 1998Google Scholar
  4. 4.
    Darwish HM, DeLuca HF: Recent advances in the molecular biology of vitamin D action. In: Progress in Nucleic Acid Research and Molecular Biology, Vol 53, Academic Press Inc, 1996, pp 321–344Google Scholar
  5. 5.
    Christakos S, Raval-Pandya M, Wernyj RP, Yang W: Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316: 361–371, 1996Google Scholar
  6. 6.
    Darwish H, DeLuca HF: Vitamin D-regulated gene expression. Critical Reviews in Eukaryotic Gene Expression 3(2): 89–116, 1993Google Scholar
  7. 7.
    Studzinski GP, McLane JA, Uskokovic MR: Signaling pathways for vitamin D-induced differentiation: Implications for therapy of proliferative and neoplastic diseases. Critical Reviews in Eukaryotic Gene Expression 3(4): 279–312, 1993Google Scholar
  8. 8.
    Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P: Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66: 121–127, 1998Google Scholar
  9. 9.
    Stevens A, Lowe JS: Male reproductive system. In: Stevens A, Lowe JS (eds) Histology, Gower Medical Publishing, London, 1992, pp 304–321Google Scholar
  10. 10.
    Weigel NL: Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319: 657–667, 1996Google Scholar
  11. 11.
    Kuiper GGJM, Brinkmann AO: Steroid hormone receptor phosphorylation: Is there a physiological role? Mol Cell Endocrin 100: 103–107, 1994Google Scholar
  12. 12.
    Norman AW, Ilka N, Zhou LX, Bishop JE, Lowe KE, Maiyar AC, Collin ED, Taoka T, Sergeev I, Farach-Carson MC: 1,25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J teroid Biochem Mol Biol 41: 231–240, 1992Google Scholar
  13. 13.
    Slater SJ, Kelly MB, Taddeo, FJ, Larkin JD, Yeager MD, McLane JA, Ho C, Stubbs CD: Direct activation of protein kinase C by 1α,25-dihydroxyvitamin D3. J Biol Chem 270: 6639–6643, 1995Google Scholar
  14. 14.
    De Boland AR, Morelli S, Boland R: 1,25-(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem 269: 8675–8679, 1993Google Scholar
  15. 15.
    Khare S, Tien XY, Wilson D, Wali RK, Bissonnette BM, Scaglione-Sewell B, Sitrin MD, Brasitus TA: The role of protein kinase-Cα in the activation of particulate guanylate cyclase by 1α,25-dihydroxyvitamin D3 in CaCo-2 cells. Endocrinology 135: 277–283, 1994Google Scholar
  16. 16.
    De Boland AR, Norman AW: Evidence for involvement of protein kinase C and cyclic adenosine 3´,5´monophosphate-dependent protein kinase in the 1,25-dihydroxyvitamin D3-mediated rapid stimulation of intestinal calcium transport (transcaltachia). Endocrinology 127: 39, 1990Google Scholar
  17. 17.
    Gniadecki R: Activation of Raf–mitogen-activated protein kinase signaling pathway by 1α25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Derm 106: 1212–1217, 1996Google Scholar
  18. 18.
    Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56: 4108–4110, 1996Google Scholar
  19. 19.
    Ingles SA, Ross RK, Yu MC, Irvine RA, Lapera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170, 1997Google Scholar
  20. 20.
    Kibel AS, Isaacs SD, Isaacs WB, Bova GS: Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 160: 1405–1409, 1998Google Scholar
  21. 21.
    Morrison AN, Qi CJ, Tokita A: Prediction of bone density from vitamin D recptor alleles. Nature 67: 284–297, 1994Google Scholar
  22. 22.
    Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7: 385–390, 1998Google Scholar
  23. 23.
    Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861–2869, 1992Google Scholar
  24. 24.
    Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10: 1307–1312, 1990Google Scholar
  25. 25.
    Wu LY, Semenya KA, Hardy RE, Hargreaves MK, Robinson SB, Pederson L, Sung JF, Haynes MA: Cancer rate differentials between blacks and whites in three metropolitan areas: A 10-year comparison. J Natl Med Assoc 90: 410–416, 1998Google Scholar
  26. 26.
    Haenszel W, Jurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43–68, 1968Google Scholar
  27. 27.
    Holick MF: The photobiology of vitamin D3 in man. In: Kumar R (ed) Vitamin D: Basic and Clinical Aspects, Martinus Nijhoff, Boston, 1984, pp 197–216Google Scholar
  28. 28.
    Campbell NJ, Elstner E, Holden S, Uskokovic M, Koeffler HP: Inhibition of proliferation of prostate cancer cells by a 19-nor hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19: 15–27, 1997Google Scholar
  29. 29.
    Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14: 1077–1081, 1994Google Scholar
  30. 30.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP: 19-nor-26,27-bishomo-vitamin D3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58: 3370–3374, 1998Google Scholar
  31. 31.
    Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ: Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3: 1331–1338, 1997Google Scholar
  32. 32.
    Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR: 1,24-dihydroxy-16-ene-23-yne-vitamin D and prostate cancer cell proliferation in vivo. Urology 46: 365–369, 1995Google Scholar
  33. 33.
    Campbell MJ, Reddy GS, Koeffler HP: Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66: 413–425, 1997Google Scholar
  34. 34.
    Hansen CM, Maenpaa PH: EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 54: 1173–1179, 1997Google Scholar
  35. 35.
    Kissmeyer AM, Binderup E, Binderup L, Hansen M, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G: Metabolism of the vitamin D analog EB1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 53: 1087–1097, 1997Google Scholar
  36. 36.
    Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC: A phase I study of vitamin D analogue EB1089 in patients with advanced breast and colorectoral cancer. Br J Cancer 78: 6–13, 1998Google Scholar
  37. 37.
    Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR: 1,25-Dihydroxyvitamin D3 induced differentiation in a human promyelocytic leukemia cell line HL-60: Receptor mediated maturation to macrophage-like cells. J Cell Biol 98: 391–398, 1984Google Scholar
  38. 38.
    Zhou JY, Norman AW, Chen DL: 1,25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87: 3929–3932, 1990Google Scholar
  39. 39.
    Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44: 693–702, 1993Google Scholar
  40. 40.
    Frappart L, Falette N, Lefebvre MF, Bremond A, Vauzelle JL, Saez S: In vitro study of effects of 1,25-ihydroxyvitamin D3 on the morphology of human breast cancer cell line BT.20. Differentiation 40: 63–69, 1989Google Scholar
  41. 41.
    Shabahang M, Buras RR, Davoodi F, Schmaker LM, Nauta RJ, Evans SR: 1,25-dihydroxyvitamin D3 receptors as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53(16): 3712–3718, 1993Google Scholar
  42. 42.
    Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54: 805–810, 1994Google Scholar
  43. 43.
    Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P: The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1,25-dihydroxyvitamin D3. Cancer Res 52: 515–520, 1992Google Scholar
  44. 44.
    Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocr 132: 1952–1960, 1993Google Scholar
  45. 45.
    de Vos S, Holden S, Heber D, Elstner E, Binderup L, Uskokovic M, Rude B, Chen D, Le J, Cho SK, Koeffler HP: Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 31: 77–83, 1997Google Scholar
  46. 46.
    Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP: 1α,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6: 727–732, 1997Google Scholar
  47. 47.
    Godyn JJ, Xu H, Zhang F, Kolla SS, Studzinski GP: A dual block to cell cycle progression in HL-60 cells exposed to analogues of vitamin D3. Cell Proliferation 27: 37–46, 1994Google Scholar
  48. 48.
    Rigby WF, Noelle RJ, Krause K, Fanger MW: The effects of 1,25-dihydroxyvitaminD3on human T lymphocyte activation and proliferation: A cell cycle analysis. J Immunol 135: 2279–2286, 1985Google Scholar
  49. 49.
    Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56: 264–267, 1996Google Scholar
  50. 50.
    Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP: Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes & Devel 10: 142–153, 1996Google Scholar
  51. 51.
    Biggs JR, Kraft AS: Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73: 509–514, 1995Google Scholar
  52. 52.
    Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Devel 9: 1149–1163, 1995Google Scholar
  53. 53.
    Sheikh MS, Rochefort H, Garcia M: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11(9): 1899–1905, 1995Google Scholar
  54. 54.
    Henkart PA: ICE family proteases: Mediators of all apoptotic cell death? Immunity 4: 195–201, 1996Google Scholar
  55. 55.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond) 348: 334–336, 1990Google Scholar
  56. 56.
    Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 4: 413–420, 1992Google Scholar
  57. 57.
    Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619, 1993Google Scholar
  58. 58.
    Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58: 367–376, 1996Google Scholar
  59. 59.
    Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, Shintaku IP, Krajewski S, Reed JC, Binderup L, Koeffler HP: Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56: 3570–3576, 1996Google Scholar
  60. 60.
    Xu H-M, Tepper CG, Jones JB, Fernandez C, Studzinski G: 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Experimental Cell Res 209: 367–374, 1993Google Scholar
  61. 61.
    McElwain MC, Dettelbach MA, Modzelewski RA, Russell DM, Uskokovic MR, Smith DC, Trump DL, Johnson CS: Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Diff 3(1): 31–50, 1995Google Scholar
  62. 62.
    Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Shurin Z, Day RS, Trump DL, Johnson CS: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999–1006, 1997Google Scholar
  63. 63.
    Modzelewski RA, Hershberger PA, Johnson CS, Trump DL: Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Amer Assoc Cancer Res 40: 580a, 1999Google Scholar
  64. 64.
    Light BW, Yu W-D, McElwain MC, Russell DM, Trump DL, Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759–3764, 1997Google Scholar
  65. 65.
    Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS: 1,25-dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21Waf1/Cip1 in vitro and in vivo. Cancer Res 59: 2644–2649, 1999Google Scholar
  66. 66.
    Berger NA: Poly (ADP-ribose) in the cellular response to DNA damage. Radiat Res 101: 4–15, 1985Google Scholar
  67. 67.
    Wintersberger U, Wintersberger E: Poly ADP-ribosylation: A cellular emergency reaction? FEBS Lett 188: 189–191, 1985Google Scholar
  68. 68.
    Green DR, Reed JC: Mitochondria and apoptosis. Science 281: 1309–1312, 1998Google Scholar
  69. 69.
    Paul A, Wilson S, Belham CM, Robin CJM, Scott PH, Gould GW, Plevin R: Stress-activated protein kinases: Activation, regulation and function. Cell Signal 96: 403–410, 1997Google Scholar
  70. 70.
    Lewis TS, Shaprio PS, Ahn NG: Signal transduction through MAP kinase cascades. Advances in Cancer Res 74: 113–139, 1998Google Scholar
  71. 71.
    McGuire TF, Trump DL, Johnson CS: Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276: 26365–26373, 2001Google Scholar
  72. 72.
    Koli K, Keski-Oja J: 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth & Differentiation 11: 221–229, 2000Google Scholar
  73. 73.
    Iseki K, Tatsuta M, Uehara G, et al.: Inhibition of angiogenesis as a mechanism for inhibition by 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81: 730–733, 1999Google Scholar
  74. 74.
    Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett 75: 35–39, 1993Google Scholar
  75. 75.
    Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM: Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Opthalmol Vis Sci 36: 83–87, 1995Google Scholar
  76. 76.
    Oikawa T, Horotani K, Nakamura O, Hiragun A, Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48: 157–162, 1989Google Scholar
  77. 77.
    Modzelewski RA, Davies P, Watkins SC, Auerbach R, Ming-Jei C, Johnson CS: Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54: 336–339, 1994Google Scholar
  78. 78.
    Ming-Jei C, Modzelewski RA, Russell DM, Johnson CS: Interleukin 1alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 56(4): 886–891, 1996Google Scholar
  79. 79.
    Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL: Anti-proliferative effects of 1α,25-dihydroxyvitamin D3 and vitamin D analogs on tumor-derived endothelial cells (submitted)Google Scholar
  80. 80.
    Heuser LS, Miller FN: Differential macromolecular leakage from the vasculature of tumors. Cancer 57: 461–464, 1986Google Scholar
  81. 81.
    Gerlowski LE, Jain RK: Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31: 288–305, 1986Google Scholar
  82. 82.
    Hori K, Suzuki M, Tanda S, Saito S: In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81: 279–288, 1990Google Scholar
  83. 83.
    Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95–109, 1988Google Scholar
  84. 84.
    Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochem Biophys Acta 1032: 89–118, 1990Google Scholar
  85. 85.
    Strom M, Sandgren ME, Brown TA, DeLuca HF: 1,25-Dihydroxyvitamin D3 up-regulates the 1,25-dihydroxyvitamin D3 receptor in vivo. Proc Natl Acad Sci USA 86: 9770–9773, 1989Google Scholar
  86. 86.
    Chen TL, Cone CM, Morey-Holton E, Feldman D: Glucocorticoid regulation of 1,25-(OH)2-vitamin D3 receptors in cultured mouse bone cells. J Biol Chem 257: 13564–13569, 1982Google Scholar
  87. 87.
    Levy J, Zuili I, Yankowitz N, Shany S: Induction of cytosolic receptors for 1,25-dihydroxyvitamin D3 in the immature rat uterus by estradiol. J Endocrinol 100: 265–269, 1984Google Scholar
  88. 88.
    Petkovich PM, Heersche JNM, Tinker DO, Jones G: Retinoic acid stimulates 1,25-dihydroxyvitamin D3 binding in rat osteosarcoma cells. J Biol Chem 259: 8274–8280, 1984Google Scholar
  89. 89.
    Reinhardt TA, Horst RL: Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrin 127: 942–948, 1990Google Scholar
  90. 90.
    Bouillon R, Okamura WH, Norman AW: Structure–function relationships in the vitamin D endocrine system. Endocrine Reviews 16: 200–257, 1995Google Scholar
  91. 91.
    Hirst M, Feldman D: Glucocorticoid regulation of 1,25-(OH)2-vitamin D3 receptors: Divergent effects on mouse and rat intestine. Endocrin 111: 1400–1402, 1982Google Scholar
  92. 92.
    Hirst M, Feldman D: Glucocorticoids down-regulate the number of 1,25-dihydroxyvitamin D3 receptors in mouse intestine. Biochem Biophys Res Comm 105: 1590–1596, 1982Google Scholar
  93. 93.
    Manolagas SC, Abare J, Deftos LJ: Glucocorticoids increase the 1,25-(OH)2 D3 receptor concentration in rat osteogenic sarcoma cells. Calcif Tissue Int 36: 153–157, 1982Google Scholar
  94. 94.
    Kimberg DV, Baerg RD, Gershon E, Graudusius RT: Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 50: 1309–1321, 1971Google Scholar
  95. 95.
    Haynes RC: Agents affecting calcification: Calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990, pp 1496–1522Google Scholar
  96. 96.
    Yu W-D, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS: Potentiation of 1,25-dihydroxyvitamin D3-mediated anti-tumor activity with dexamethasone. J Natl Cancer Inst 90: 134–141, 1998Google Scholar
  97. 97.
    Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS: Combination of 1α,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7: 4164–4173, 2001Google Scholar
  98. 98.
    Norman AW: The mode of action of vitamin D. Biol Rev 243: 4055–4064, 1968Google Scholar
  99. 99.
    Hershberger PA, Yu W-D, Modzelewski RA, Rueger RM, Johnson CS, Trump DL: Enhancement of paclitaxel antitumor activity in squamous cell carcinoma and prostatic adenocarcinoma by 1,25-dihydroxycholecaciferol (1,25-D3) Cancer Res 7: 1043–1051, 2001Google Scholar
  100. 100.
    Koeffler HP, Hirji K, Iltri L, the Southern California Leukemia Group: 1,25-Dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69: 1399–1407, 1985Google Scholar
  101. 101.
    French LE, Ramelet AA, Saurat J-H: Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. Lancet 344: 686–687, 1994Google Scholar
  102. 102.
    Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle CS, Soukop M: Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Brit Med J 291: 1153–1155, 1985Google Scholar
  103. 103.
    Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A phase I trial of subcutaneous calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339–1345, 1999Google Scholar
  104. 104.
    Beer TM, Munar M, Henner WD: A phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer 91: 2431–2439, 2001Google Scholar
  105. 105.
    Osborne JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL: Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195–198, 1995Google Scholar
  106. 106.
    Gross C, Stamey T, Hancock S, Feldman D: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159: 2035–2040, 1998Google Scholar
  107. 107.
    Davies M: High-dose vitamin D therapy: Indications, benefits and hazards. In: Walter P, Brubacher G, Stahelin H (eds) Elevated Dosages of Vitamins, Vol 81, Hans Huber, Lewistown, NY, 1989Google Scholar
  108. 108.
    Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump DL, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. J Clin Oncol 17: 2506–2513, 1999Google Scholar
  109. 109.
    Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590–597, 1989Google Scholar
  110. 110.
    Small EJ, Meyer M, Marshall, ME, Reyno LM, Meyers FJ, Natale RB, Lenchan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18(7): 1440–1450, 2000Google Scholar
  111. 111.
    Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, Petrylak DP: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163(3): 834–837, 2000Google Scholar
  112. 112.
    Trump DL, Serafine S, Brufsky A, Potter D, Johnson CS: High dose calcitriol (1,25(OH)2 vitamin D3) + dexamethasone in androgen independent prostate cancer (AIPC). Proc Amer Soc Clin Oncol 19: 337a, 2000Google Scholar
  113. 113.
    Johnson CS, Egorin MJ, Zuhowski R, Parise R, Cappozolli M, Belani CP, Long GS, Muindi J, Trump DL: Effects of high dose calcitriol (1,25-dihydroxyvitamin D3) on the pharmacokinetics of paclitaxel or carboplatin: Results of two phase I studies. Proc Amer Soc Oncol 19: 210a, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Candace S. Johnson
    • 1
  • Pamela A. Hershberger
    • 2
  • Donald L. Trump
    • 3
  1. 1.Department of Pharmacology & TherapeuticsRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Department of PharmacologyUniversity of PittsburghPittsburghUSA
  3. 3.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations